key: cord-0746006-pujey3no
authors: Wu, Hanting; Dai, Rongchen; He, Peijie; Liang, Juan; Li, Qiushuang; Yang, Junchao; Lu, Hanti; Guo, Qing; Mao, Wei; Ji, Conghua
title: Characteristics analysis for clinical study design relating to COVID-19 based on the database of ClinicalTrials.gov
date: 2022-01-10
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.01.015
sha: 68228c648e5b2bf2fae020f6021b5669e3c49d07
doc_id: 746006
cord_uid: pujey3no

Background and Objective The outbreak of the novel coronavirus disease (COVID-19) is currently ravaging worldwide. A large number of studies were registered and conducted in rapid response to the epidemic, but how to choose the proper design for clinical trials still remains the main concern. This study aimed to determine fundamental characteristics of study design during the COVID-19 epidemic and provide references for other emerging infectious diseases. Methods We searched the database of ClinicalTrials.gov with the keyword 'COVID-19′ and compared them with the design features of other conventional studies except for COVID-19. Results From January 1, 2020 to September 30, 2021, 55 334 trials were registered at ClinicalTrials.gov. Of all the registered trials, 6408 were related to COVID-19(11.58%). There were significant differences in the proportion of observational studies between COVID-19 (43.48%) and others (23.27%). The completion rate of observational trials and interventional trials in COVID-19 was 29.04% and 25.84%, respectively. COVID-19 trials showed a higher rate of completion than others (P<0.01). The time distribution and trend of observational studies and interventional studies varied considerably. Conclusion Appropriately designed trials can help to improve research efficiency and reduce the possibility of research failure. In addition to randomized controlled trials, observational and single-armed studies are also worth considering.

The outbreak of the novel coronavirus disease (COVID-19) is currently ravaging worldwide. Timely identification and cutting off the route of transmission can control the source of infection (Lotfi, et al.,2020 , Saran, et al.,2020 , Ting Wu H,2021 . On this basis, the medical system will face the dilemma of how to treat patients effectively.

Due to the particularity of emerging infectious diseases, it will bring difficulties to the selection of research and design schemes. As the disease is threatening, the first must be empirical symptomatic treatment or exploratory treatment with existing drugs. However, sometimes when we prepare for a long-term large-scale clinical study, the epidemic is over and there are no patients to perform trials. A report published by a committee of the US National Academies of Sciences, Engineering and Medicine, which reviewed clinical researches conducted during the outbreak of Ebola, also expressed similar concerns(National Academies of Sciences, et al.,2017) . These particularities doomed the choice of clinical research design scheme of new infectious diseases to be different from general diseases. Therefore, we review the clinical study design relating to COVID-19 registered in ClinicalTrials.gov since January 2020 aimed to determine fundamental characteristics of study design during COVID-19 epidemic and provide reference for other emerging infectious diseases.

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. In 1997, the United States Congress mandated the creation of the ClinicalTrials.gov registry to assist people in gaining access to trials (Califf, et al.,2012) . In September 2004, the International Committee of Medical Journal Editors (ICMJE) made a statement that only trials registered before the beginning of patient recruitment would be considered for publication (De Angelis, et al.,2005) . In order to improve the diagnosis, treatment and prevention of this disease, many clinical trials have been registered and carried out all over the world since the outbreak of COVID-19. We also noticed that there were several pieces of literature collecting the registered COVID-19 trials, but mainly focused on interventional trials and the characteristics in terms of participants, interventions and outcomes (Jones, et al.,2020 , Wang, et al.,2020 , Luo, et al.,2021 . By searching for the characteristics of all clinical research design schemes about covid-19 registered in this database since January 2020 and comparing them with the characteristics of other conventional studies except covid-19, we can find the clinical research design rules and features of new infectious diseases, which will help us to select more appropriate research design schemes for new infectious diseases in the future. We also aim to provide evidence for improving research efficiency and reducing the possibility of research failure.

We searched the database of ClinicalTrials.gov with the keyword 'COVID-19', without restriction on languages and study type. The search time was limited from January 1, 2020 to September 30, 2021. The registration information of all relevant studies was downloaded. At the same time, the details of all clinical trials registered after January 2020 were also collected to compare the characteristics of trials. The search was performed on October 4, 2021.

Two researchers independently collected data from the downloaded registration information files, after which a third researcher checked the data.

The following information was collected from each study: title, date of registration, current status, locations, study type, study designs, interventions and control, sponsor and collaborators, phases, sample size, outcomes and recruiting status. The overall status of registered clinical trials on COVID-19 was reviewed and collated.

We reported absolute numbers and percentages for categorical variables and compared them by using χ 2 analysis. Analyses were conducted on the design, study type and time distribution of registered trials.

From January 1, 2020 to September 30, 2021, 55 334 trials were registered at ClinicalTrials.gov. Of all the registered trials, 6408 were related to COVID-19(11.58%).

Overall numbers of identified trials and comparisons by study type of registered clinical trials are presented in proportions of patient registry studies between COVID-19 trials and the other trials was also significant (P<0.001).

All interventional studies were grouped according to the method of allocation and further divided into five intervention models: crossover assignment, factorial assignment, parallel assignment, sequential assignment and single group assignment.

Random allocation was used in the 2673(73.80%) COVID-19 trial and 23970(63.85%) the other trials. Randomized studies accounted for the largest proportion in both COVID-19 trials and the others, and the ratio of randomized studies in COVID-19 trials was significantly higher than in the other trials (P<0.001). Furthermore, the difference of proportion in randomized studies with crossover, parallel and sequential assignment between COVID-19 and the other trials was also significant (P<0.001). For 618(17.06%) COVID-19 trials and 9988(26.61%) the other trials in which allocation methods were not applicable, the intervention model of single group assignment was mostly (n=608, n=9654) used.

Non-random allocation was used in 330(9.11%) COVID-19 trials and 3545(9.44%) the other trials and the difference was not statistically significant.

More details were shown in TABLE 2. The completion rate of intervention trials related to COVID-19 was significantly higher than that of the other clinical trials (P<0.001).

The analysis of observational studies shows the same result with completion rates of 29.04% and 11.57% in the COVID-19 trials and the others, respectively (P<0.001).

Statistical analysis was also performed in all identified trials. In comparison to those of COVID-19 clinical trials, the ratio of recruiting trials that had not started recruiting was significantly higher(P<0.001) in the other clinical trials and the completion rate was still lower(P<0.001). For interventional studies, the proportion of trials with single-grouped assignments also showed a decreasing tendency by season in 2020.

Although the total number of observational studies (n=2786) and interventional studies (n=3662) showed similarly, the time distribution and trend of quantity varied considerably (figure1).

Emerging and sudden infectious diseases (such as Ebola, Middle East respiratory syndrome and COVID-19) have brought great harm to human health. Since the first outbreak of COVID-19 in China from an unknown origin, this newly emerging respiratory disease quickly became a global pandemic.

Countries around the world have called for the launching of clinical trials and rapidly expanding response activities of emerging infectious diseases to seek new therapeutic strategies and specific medicine.

Among all the clinical trials, there is no doubt that RCT is the optimal way to evaluate new therapeutic with the highest level of grading quality of evidence (Byar, et al.,1976 , Bothwell, et al.,2016 . However, at the beginning of the COVID-19 outbreak, how long will the disease last and how many patients will be infected remains unclear. Limited information of its source of initial infection, pathogenesis, route of transmission and clinical outcomes in hospitalized patients with COVID-19 also caused difficulty in the design of RCT. By comparison, the design of observational studies was affected little by these factors.

Statistics in our analysis also showed that the observational studies accounted for the largest part of COVID-19 clinical trials at the beginning of the epidemic and the ratio of it in COVID-19 trials was significantly higher than in other contemporaneous trials. For newly emerging infectious diseases, there were no proven safe and effective therapeutic products or vaccines when the epidemic began. Selection of treatment in the control group remained difficult and it was considered unethical to use placebos in face of a disease without adequate knowledge (Ellenberg, et al.,2018) . It also usually took long for interventional trials to be planned, vetted, and initiated. In such cases, it is not an unattractive option to quickly start observational studies in consideration of the emergency of the disease, and evidence from welldesigned observational studies can be helpful in filling evidence gaps. Failure to react quickly may lead to a missed opportunity to collect reliable clinical evidence if the outbreak subsides. Furthermore, beyond generally taking less time and money to conduct, observational studies have a number of strengths such as reducing potential harms associated with interventional research when equipoise is unclear and capturing diverse patient populations (Gershon, et al.,2021) . With the further cognition of the disease and the development of research, the proportion of interventional trials increased gradually. But according to TABLE 4, the completion rate of observational trials and interventional trials in COVID-19 was 29.04%, and 25.84% until 4 October 2021, respectively. In contrast to interventional trials, observational studies usually started earlier during the outbreak. And as the epidemic approached its waning in China, patients eligible for interventional trials became fewer and fewer, and many trials had to be stopped.

The single-arm trials constituted an important part of registered interventional clinical trials during the pandemic of COVID-19. Single-arm designs have the advantage of being easier to employ as pragmatic trials and requiring fewer patients, and all of them receive the experimental treatment (Philip, et al.,2014 , Ventz, et al.,2019 . With limitations on time and therapeutic method, an expedited result through a single-arm trial is desirable when feasible, and may enable an efficacious treatment into larger confirmatory studies before the epidemic waned, or to allow an ineffective approach to be abandoned for trials of other possible treatments (Whitehead, et al.,2016 , Brueckner, et al.,2018 .

There were also several limitations in our study.

First of all, Different design of studies has their own characteristics and advantages, it's of vital importance to make trade-offs between these methods of research.

This work makes a comparison on the characteristics between COVID-19 trials and other trials registered during the same period and summarizes the time distribution of COVID-19 clinical trials, trying to collect existing evidence and help to identify trial designs most likely to succeed at a particular point during an outbreak.

Our research suggests that the choice of study design is of vital importance in face of emerging infectious diseases. Appropriately designed trials can help to improve research efficiency and reduce the possibility of research failure. RCTs have the highest quality of evidence, but there are various barriers to their effective implementation during the epidemic.

Observational and single-armed studies should be attached importance as well. Further study can focus more on clinical trial design processes.

The authors declare no conflicts of interest. 

The Emergence of the Randomized, Controlled Trial

Performance of different clinical trial designs to evaluate treatments during an epidemic

Randomized clinical trials. Perspectives on some recent ideas

Characteristics of clinical trials registered in ClinicalTrials.gov

Is this clinical trial fully registered?--A statement from the International Committee of

Rigorous Clinical Trial Design in Public Health Emergencies Is Essential

Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement

Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis

COVID-19: Transmission, prevention, and potential therapeutic opportunities

Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): A scoping review

Board on Health Sciences P, Board on Global H et al. In: Integrating Clinical Research into Epidemic Response: The Ebola Experience

Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials

Personal protective equipment during COVID-19 pandemic: a narrative review on technical aspects

Effects of air-conditioning systems in the public areas of hospitals: A scoping review

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data

Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov

Trial design for evaluating novel treatments during an outbreak of an infectious disease